The thymolytic effect of cocaine and monoaminergic drugs in the mouse

Life Sciences

Volumn 62, Issue 10, 1998, Pages 905-912

  Choi, Sun Ju ^a   Yoon, Kyoung Jin ^a   Park, Kwan Kyun ^a   Ngong, Josephine M ^a   Soliman, Karam F A ^a  

^a FLORIDA A AND M UNIVERSITY   (United States)

Author keywords

Cocaine; DNA synthesis; Immune suppression; Thymidine; Thymocyte

Indexed keywords

ADRENALIN; APOMORPHINE; COCAINE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; DOSE RESPONSE; IMMUNITY; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; THYMOCYTE; THYMUS ATROPHY;

ANIMALS; APOMORPHINE; BIOGENIC MONOAMINES; BRAIN; COCAINE; DNA; HALOPERIDOL; MALE; MICE; ORGAN SIZE; THYMIDINE; THYMUS GLAND;

ANIMALIA;

EID: 0032579217     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(98)00008-3     Document Type: Article

References (27)

1. 1. R.B. ROTHMAN, Life Sci. 46 17-21 (1990).
2. 2. B. WATZEL, and R.R. WATSON, Life Sci. 46 1319-1329 (1990).
3. 3. C. STERK, Lancet ii 1052 (1988).
4. 4. R.E. CHAISSON, P. BACCHIETTI, D. OSMOND, B. BRODIE, M.A. SANDE, and A.R. MOSS, JAMA 261 561 (1989).
5. 5. S.H. WEISS, JAMA 261 607-609 (1989).
6. 6. F.H. GAWIN, and E.H. EFFINWOOD, N. Engl. J. Med. 318 1173-1180 (1988).
7. 7. M.C. RITZ, R.J. LAMB, S.R. GOLDBERG, and M.J. KUHAR, Science 237 1219-1223 (1987).
8. 8. V.K. SHUKLA, L.R. GOLDFRANK, H. TURNFORF, and M. BANSINATH, Life Sci. 49 1887-1893 (1991).
9. 9. U.C. GRAG, H. TURNDORF, and M. BANSINATH, Neuroscience 57 467-472(1993).
10. 10. S.K. SOBRIAN, L.E. BURTON, N.E. ROBINSON, W.K. ASHE, H. JAMES, D.L. STOKES, and L.M. TURNER, Pharm. Biochem. Behav. 35 617-629 (1990).
11. 11. W.T. ADAMSON, R.T. WINDH, S. BLACKFORD, and C.M. KUHN, Endocrinology 1129 959-964 (1991).
12. 12. J.C. BUCKINGHAM, Neuroendocrinology 35 111-116 (1992).
13. 13. N.S. PILOTTE, L.G. SHARPE, and E.M. DAX, Brain Res. 512 107-112 (1990).
14. 14. C. RIVIER, and W. VALE, Brain Res. 422 403-406 (1987).
15. 15. B.M. BAYER, S.E. MULRONEY, M.C. HERNANDEZ, and X.Z. DING, Immunopharmacology 29 19-18 (1995).
16. 16. M.C. LOPEZ, and R.R. WATSON, Life Sci. 54 147-151 (1994).
17. 17. B. BOROWSKY, and C.M. KUHN, J. Pharmac. Exp. Ther. 256 204-210 (1991).
18. 18. M.H. MARKMAN, B. DVORKIN, and A. WHITE, J. Biol. Chem. 241 1646-1648 (1989).
19. 19. G.D. ROVALL, L. MCGURK, R.F. SMITH, M. COSS, P. NAYLOR, and K.K. OATES, Soc. Neurosci. Abs. 17 (1991).
20. 20. M. HOLSAPPLE, and A. MUNSON, Immunotoxicology of abused drugs, Immune toxicology and Immunopharmacology, J. Dean (ed), 381-392, Raven Press, New York (1985).
21. 21. J.M. RITCHIE, and N.M. GREENE, Pharmcological Basis of Therapeutics, A.G. Gilman, L.S. Goodman, T.W. Rall, F. Murad, (eds), 302-321, MacMillan, New York, (1985).
22. 22. A.D. LEVY, Q. LI, M.C.A. SANZ, P.A. RITTENHOUSE, J.E. KERR, and L.D. WAN DE KAR, Life Sci. 51 887-897 (1992).
23. 23. R.K. CONLEE, D.W. BARNETT, K.P. KELLY, and D.H. HAN, Metabolism 40 1043-1047 (1991).
24. 24. N.E. GOEDERS, O.J. BIENVENU, and E.B. DE SOUZA, Brain Res. 531 322-328 (1990).
25. 25. R.L. MOLDOW, and A.J. FISCHMAN, Peptides 8 819-822 (1987).
26. 26. A. RICCI, D. ZACCHEO, and F. AMENTA, Funct. Neurol. 6 223-225 (1991).
27. 27. H. OVADIA, I. LUBETZKI-KORN, and O. ABRAMSKY, Ann N Y Acad Sci. 496 211-216 (1987).